In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors
- 1 May 2006
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 112 (3), 312-319
- https://doi.org/10.1016/j.jconrel.2006.03.001
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumorJournal of Controlled Release, 2005
- Biodistribution and Targeting Potential of Poly(ethylene glycol)-modified Gelatin Nanoparticles in Subcutaneous Murine Tumor ModelJournal of Drug Targeting, 2004
- Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: Potentiation by Cox‐2 inhibitionInternational Journal of Cancer, 2004
- Paclitaxel nanoparticles for the potential treatment of brain tumorsJournal of Controlled Release, 2004
- Specific Association of Thiamine-Coated Gadolinium Nanoparticles with Human Breast Cancer Cells Expressing Thiamine TransportersBioconjugate Chemistry, 2003
- Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell LineJapanese Journal of Cancer Research, 2002
- LIPOSOMAL DAUNORUBICIN OVERCOMES DRUG RESISTANCE IN HUMAN BREAST, OVARIAN AND LUNG CARCINOMA CELLSJournal of Liposome Research, 2002
- Intracellular Levels of Two Cyclosporin Derivatives Valspodar (PSC 833) and Cyclosporin A Closely Associated with Multidrug Resistance-modulating Activity in Sublines of Human Colorectal Adenocarcinoma HCT-15Japanese Journal of Cancer Research, 2001
- Process of Dispersion and Fragmentation of Golgi Complex by Microtubule Bundles Formed in Taxol Treated HeLa Cells.Cell Structure and Function, 1997
- The Multidrug Resistance‐associated Protein Gene Confers Drug Resistance in Human Gastric and Colon CancersJapanese Journal of Cancer Research, 1996